Evariant, the leading healthcare CRM data analytics platform, announced today it is a Diamond Sponsor of SHSMD Connections 2017, the premier conference for healthcare marketing, public relations and communications, and strategic planning professionals, taking place at the Marriott World Center in Orlando, FL on September 24-27, 2017. More
September 21, 2017
Evariant Named Recipient of Marcum Tech Top 40 Award as one of Connecticut’s Fastest Growing Tech Companies
September 20, 2017
The Connecticut Technology Council (CTC) and Marcum LLP announced Evariant, the leading healthcare CRM data analytics platform, has made the Marcum Tech Top 40 (TT40) list of fastest growing technology companies in Connecticut. This marks the sixth consecutive year Evariant was recognized on the TT40 list in the Software category. Evariant was honored alongside 39 other TT40 companies at an awards ceremony September 19 at the Oakdale Theatre in Wallingford. More
August 31, 2017
Evariant, a healthcare CRM data analytics platform, today announced that it was identified as a sample vendor in the Gartner “Hype Cycle for Healthcare Providers, 20171” report. This report can help health system CIOs identify, understand, and prioritize significant investments in applications, analytics, and “medical IT” advances. Evariant was named in the Healthcare CRM/Contact Center Systems category. More
July 19, 2017
Evariant, the leading healthcare CRM data analytics platform, today announced that it has appointed Thomas (Tom) Schultz as Chief Growth Officer. Schultz will join the company July 31st.
In his role at Evariant, Schultz will oversee the company’s revenue growth strategy and play a critical role in developing the company’s corporate, product, and go-to-market strategies. Schultz will report to Chief Executive Officer Clay Ritchey. More
March 29, 2017
Evariant, the leading healthcare CRM data analytics platform, today announced that it has appointed Clay Ritchey as Chief Executive Officer effective March 20. William Moschella, Evariant’s co-founder and former CEO, will remain on the company’s board of directors and senior leadership team.
“This marks an important milestone for Evariant as we continue rapid growth and customer expansion,” said Moschella. “Clay shares my passion for enabling customer success and growth in the healthcare market and is the right person to lead Evariant through the next stage of hyper growth.” More